iBio (IBIO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock.
iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap” [Yahoo! Finance]
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3 [Yahoo! Finance]
iBio (IBIO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock.